Novavax

Two months later there is still no sign of a decision from regulators. Novavax Inc on Monday revealed a sharp drop in first-quarter COVID-19 research funding and said it shipped less than a fourth of the total vaccine deliveries slated for 2022 dragging shares of.

Pin On Aa Coronavirus

We would like to show you a description here but the site wont allow us.

. Novavax reported first-quarter revenue of 704 million which came in below the 8452 million estimate. Novavax filed for emergency use for its COVID-19 vaccine with the FDA Jan. The company reported quarterly earnings of 256 per share which came in below the.

Novavax is the first protein-based COVID-19 vaccine to be provisionally approved by the Therapeutic Goods Administration TGA. Inclusivity in clinical trials. Novavax stock was dropping Friday after receiving a Sell-equivalent rating the first since December 2020 and the only one from Wall Street.

Novavaxs submission includes data from a late-stage trial in the US where the vaccine showed 80 efficacy among adolescents when Delta was the dominant variant in the country. It has been proven safe and effective in protecting against severe illness or death associated with COVID-19 infection with clinical trial data showing a robust immune response providing around 90 per cent protection. Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Bank of America Securities analyst Alec Stranahan. We would like to show you a description here but the site wont allow us.

Pin On Stock News And Tips